Cited by 342Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical ImagingArtificial Intelligence in Healthcare and Education

Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review

Open access
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S.E., Mazzeo, L. +22 more·2024·Annals of Oncology

Abstract

Background The widespread use of immune checkpoint inhibitors (ICIs) has revolutionised treatment of multiple cancer types. However, selecting patients who may benefit from ICI remains challenging. Artificial intelligence (AI) approaches allow exploitation of high-dimension oncological data in research and development of precision immuno-oncology.Materials and methods We conducted a systematic literature review of peer-reviewed original articles studying the ICI efficacy prediction in cancer patients across five data modalities: genomics (including genomics, transcriptomics, and epigenomics), radiomics, digital pathology (pathomics), and real-world and multimodality data.Results A total of 90 studies were included in this systematic review, with 80% published in 2021-2022. Among them, 37 studies included genomic, 20 radiomic, 8 pathomic, 20 real-world, and 5 multimodal data. Standard machine learning (ML) methods were used in 72% of studies, deep learning (DL) methods in 22%, and both in 6%. The most frequently studied cancer type was non-small-cell lung cancer (36%), followed by melanoma (16%), while 25% included pan-cancer studies. No prospective study design incorporated AI-based methodologies from the outset; rather, all implemented AI as a post hoc analysis. Novel biomarkers for ICI in radiomics and pathomics were identified using AI approaches, and molecular biomarkers have expanded past genomics into transcriptomics and epigenomics. Finally, complex algorithms and new types of AI-based markers, such as meta-biomarkers, are emerging by integrating multimodal/multi-omics data.Conclusion AI-based methods have expanded the horizon for biomarker discovery, demonstrating the power of integrating multimodal data from existing datasets to discover new meta-biomarkers. While most of the included studies showed promise for AI-based prediction of benefit from immunotherapy, none provided high-level evidence for immediate practice change. A priori planned prospective trial designs are needed to cover all lifecycle steps of these software biomarkers, from development and validation to integration into clinical practice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2023.10.125

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multimodal deep learning integrates histopathology, radiology, genomics, and clinical records to create unified patient-level representations.

    “The most active line of work is multimodal deep learning (MDL), which integrates histopathology (“pathomics”), radiology (“radiomics”), genomics, and clinical records to create unified patient-level representations [70,71,72] (Figure 4).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 150 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. https://doi.org/10.1016/j.annonc.2023.10.125 Volume 35 -Issue 1 -2024 https://doi.org/10.1016/j.annonc.2023.10.125 Volume 35 -Issue 1 -2024 REFERENCES · DOI
  2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell nonesmall-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
  3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1epositive nonesmall-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
  4. Ilse M, Jakub T, Max W. "Attention-based deep multiple instance learning." International conference on machine learning. PMLR; 2018. p. 2127-2136.
  5. Kipf TN, Welling M. Semi-supervised classification with graph con- volutional networks. The International Conference on Learning Rep- resentations (ICLR). Published online September 9. 2016. http://arxiv. org/abs/1609.02907.
  6. NCBI. Gene Expression Omnibus. Available at https://www.ncbi.nlm. nih.gov/geo/. Accessed February 3, 2023.

Cited by

Sorted by citations

Authors
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., Favali, M., Spagnoletti, A., Castelo-Branco, L., Dolezal, J., Pearson, A. T., Lo Russo, G., Proto, C., Ganzinelli, M., Giani, C., Ambrosini, E., Turajlic, S., Au, L., Koopman, M., Delaloge, S., Kather, J. N., de Braud, F., Garassino, M. C., Pentheroudakis, G., Spencer, C., & Pedrocchi, A. L. G.
Affiliations
  • European Society for Medical Oncology (CH)
  • Fondazione Politecnico di Milano (IT)
  • Aalborg University (DK)
  • Ospedale Policlinico San Martino (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Ospedale San Paolo (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Politecnico di Milano (IT)
  • University of Chicago (US)
  • The Francis Crick Institute (GB)
  • Royal Marsden NHS Foundation Trust (GB)
  • Else Kröner Fresenius Center for Digital Health (DE)
Corresponding author
Prelaj, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2024-01
Volume
35
Issue
1
Pages
29-65
ISSN
0923-7534 (ISSN-L)
OpenAlex
W4387881611
Cited by
340
References
150
Citations by year
2026: 131 · 2025: 149 · 2024: 60
FWCI
11.08
Type
journal article
Language
en
Open access
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (acceptedVersion, other-oa)
  • Virtual Community of Pathological Anatomy (University of Castilla La Mancha) (submittedVersion, other-oa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Funders
  • Gilead Sciences
  • AbbVie
  • Cancer Research Foundation
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
Keywords
artificial intelligence, predictive biomarkers, immune checkpoint inhibitors, cancer immunotherapy, immunotherapy response prediction, radiomics, digital pathology, pathomics, genomics, transcriptomics, epigenomics, multimodal data integration, non-small cell lung cancer, melanoma, precision oncology
MeSH terms
Artificial Intelligence, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Medical Oncology, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review